Genoway (France) Executives
| ALGEN Stock | EUR 3.93 0.09 2.34% |
Discussion of Genoway's management performance can provide insight into the enterprise performance.
| Alexandre Fraichard Chairman Chairman of the Board and CEO |
Genoway |
Genoway Management Team Effectiveness
Genoway's management efficiency ratios could be used to measure how well Genoway manages its routine affairs as well as how well it operates its assets and liabilities.Genoway Workforce Comparison
Genoway is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 622. Genoway totals roughly 128 in number of employees claiming about 21% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.03 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Genoway Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genoway Price Series Summation is a cross summation of Genoway price series and its benchmark/peer.
Genoway Stakeholder
| Alexandre Fraichard | Chairman of the Board and CEO | Profile |
About Genoway Management Performance
The success or failure of an entity such as Genoway often depends on how effective the management is. Genoway management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genoway management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genoway management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company was founded in 1999 and is based in Lyon, France. GENOWAY operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 105 people.
Genoway Workforce Analysis
Traditionally, organizations such as Genoway use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Genoway within its industry.Genoway Manpower Efficiency
Return on Genoway Manpower
| Revenue Per Employee | 109.5K | |
| Net Loss Per Employee | 2.5K | |
| Working Capital Per Employee | 23.4K |
Additional Tools for Genoway Stock Analysis
When running Genoway's price analysis, check to measure Genoway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genoway is operating at the current time. Most of Genoway's value examination focuses on studying past and present price action to predict the probability of Genoway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genoway's price. Additionally, you may evaluate how the addition of Genoway to your portfolios can decrease your overall portfolio volatility.